Tendyne™ - Features

TENDYNE^™
MITRAL VALVE
REPLACEMENT
TRANSCATHETER MITRAL VALVE
REPLACEMENT (TMVR)

Tendyne™ TMVR System is first-in-class technology designed to eliminate Mitral Regurgitation (MR),
offering selected patients with MR (≥ grade 3) a novel option for mitral valve replacement.

Features

DESIGNED FOR THE MITRAL ANATOMY TO ELIMINATE MR

TENDYNE™ eLABELLING SITE

TREAT MORE MR

IMPLANT WITH CONFIDENCE¹

A wide array of sizes to provide appropriate fit for paravalvular sealing and LVOT area
AP dimension (mm): 26.4–41.3
Perimeter (mm): 96–143
Repositionable and retrievable intraoperatively, even after the valve is deployed
Robust pre-procedural planning support

Connext
Live

Bringing together the cardiovascular and stroke prevention community for live virtual events with the most respected KOLs.

Find out more

TV

AV VALVES 2023: MR – MAC

AV VALVES Summit 2023 Case Parade Mitral: MAC

EuroPCR 2022: Mitral replacement

EuroPCR 2022: Mitral replacement – expanding patient options

EuroPCR 2022: Tendyne™

EuroPCR 2022: Expand your mitral portfolio with Tendyne™

EACTS 2022: Tendyne™ vs on-pump MVR

EACTS 2022 Symposium: When can Tendyne™ TMVR be a relevant substitute for on-pump MVR?

EACTS 2022: SMV repair vs replacement

EACTS 2022 Symposium: Surgical Mitral Valve Repair versus Replacement in the Modern Era of Transcatheter Valve Interventions.

ESC 2022: How do I manage my patient with functional mitral regurgitation.mp4

ESC 2022: FMR

ESC 2022: How do I manage my patient with functional mitral regurgitation?

SES_PLV_21_11_22_LL_1015_ID125_57_Abbott.mp4

PCRLV 2021: Transcatheter mitral valve replacement

PCRLV 2021: Transcatheter mitral valve replacement: patient selection & hemodynamic stability

EACTS 2021: Transcatheter mitral valve implantation

EACTS 2021: Transcatheter mitral valve implantation: patient selection & medical management

Tendyne™: Animation

Tendyne™ Procedural Animation: Quality Time Secured

References

*The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual’s experience and might not be representative of others.

**Tests performed by and data on file at Abbott.

Tendyne™ IFU.
Data on file at Abbott.
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–1011.
doi.org/10.1016/S0140-6736(06)69208-8.
United States Census Bureau, 2010. Age and sex composition. Issued May 2011:1–16.
Mirabel M, Lung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358–1365.
doi.org/10.1093/eurheartj/ehm001.
Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes With Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70(19):2315–27.
doi.org/10.1016/j.jacc.2017.09.015.
Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol. 2019;73(11):1250–1260.
doi.org/10.1016/j.jacc.2018.12.066.
Gammie JS, Chikwe J, Badhwar V, et al. Isolated Mitral Valve Surgery: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis.
Ann Thorac Surg. 2018;106(3):716–27.
doi.org/10.1016/j.athoracsur.2018.03.086.

IMPLANT WITH CONFIDENCE1